Defining muscle-invasive bladder cancer immunotypes by introducing tumor mutation burden, CD8+ T cells, and molecular subtypes

Immunotherapy, especially anti-PD-1, is becoming a pillar of modern muscle-invasive bladder cancer (MIBC) treatment. However, the objective response rates (ORR) are relatively low due to the lack of precise biomarkers to select patients. Herein, the molecular subtype, tumor mutation burden (TMB), an...

Descripción completa

Detalles Bibliográficos
Autores principales: Chen, Zihao, Liu, Guojun, Liu, Guoqing, Bolkov, Mikhail A., Shinwari, Khyber, Tuzankina, Irina A., Chereshnev, Valery A., Wang, Zhifeng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778803/
https://www.ncbi.nlm.nih.gov/pubmed/33388091
http://dx.doi.org/10.1186/s41065-020-00165-7

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7778803/
https://www.ncbi.nlm.nih.gov/pubmed/33388091
http://dx.doi.org/10.1186/s41065-020-00165-7

Ejemplares similares